Brandes reports 0.22% stake in Avadel

Brandes Investment Partners, L.P., a Delaware investment adviser, reports beneficial ownership of 218,835 common shares of Avadel Pharmaceuticals plc, equal to 0.22% of the class as of December 31, 2025.

Rhea-AI Filing Summary

Brandes Investment Partners, L.P., a Delaware investment adviser, reports beneficial ownership of 218,835 common shares of Avadel Pharmaceuticals plc, equal to 0.22% of the class as of December 31, 2025. All voting and dispositive power over these shares is reported as shared, with no sole authority.

The filing is made on a passive Schedule 13G basis, with Brandes certifying that the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Avadel.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What percentage of Avadel (AVDL) shares does Brandes Investment Partners report owning?

Brandes Investment Partners reports owning 0.22% of Avadel’s common shares. This corresponds to 218,835 shares and reflects a relatively small, passive stake rather than a controlling or activist position in the company’s equity structure.

How many Avadel (AVDL) shares are beneficially owned by Brandes Investment Partners?

Brandes Investment Partners reports beneficial ownership of 218,835 Avadel common shares. All of these shares are reported with shared voting and shared dispositive power, meaning Brandes does not claim sole authority over voting or selling these shares.

Is Brandes Investment Partners’ stake in Avadel (AVDL) a passive investment?

Yes. Brandes certifies the shares were acquired and are held in the ordinary course of business. The filing states they are not held for the purpose of changing or influencing control of Avadel, consistent with a passive Schedule 13G filing.

What type of filer is Brandes Investment Partners in this Avadel (AVDL) Schedule 13G/A?

Brandes Investment Partners is identified as an investment adviser. The filing cites its status in accordance with Rule 13d-1(b)(1)(ii)(E), which covers institutional investment advisers reporting beneficial ownership on a Schedule 13G basis.

Does Brandes Investment Partners have sole voting power over its Avadel (AVDL) shares?

No. The filing reports zero shares with sole voting power and 218,835 shares with shared voting power. Similarly, Brandes reports no sole dispositive power and shared dispositive power over the entire 218,835-share position.

As of what date is Brandes’ Avadel (AVDL) ownership information reported?

The ownership information is reported as of December 31, 2025. That date is used as the event date requiring the Schedule 13G/A filing, anchoring the 218,835-share, 0.22% ownership figures disclosed by Brandes.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/12/2026 - 04:17 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

AVADEL PHARMACEUTICALS PLC

(Name of Issuer)

Common Shares

(Title of Class of Securities)

G29687103

(CUSIP Number)

12/31/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. G29687103

1

Names of Reporting Persons

BRANDES INVESTMENT PARTNERS, LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 218,835.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 218,835.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

218,835.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.2 %

12

Type of Reporting Person (See Instructions)

IA, PN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: AVADEL PHARMACEUTICALS PLC
(b)	Address of issuer's principal executive offices: 10 EARLSFORT TERRACE, DUBLIN 2, IRELAND, D02 T380.
Item 2.
(a)	Name of person filing: Brandes Investment Partners, L.P.
(b)	Address or principal business office or, if none, residence: 4275 Executive Square, 5th Floor, La Jolla, CA 92037
(c)	Citizenship: Delaware
(d)	Title of class of securities: Common Shares
(e)	CUSIP No.: G29687103
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 218,835
(b)	Percent of class: 0.22 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0
	(ii) Shared power to vote or to direct the vote: 218,835
	(iii) Sole power to dispose or to direct the disposition of: 0
	(iv) Shared power to dispose or to direct the disposition of: 218,835
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

BRANDES INVESTMENT PARTNERS, LP

Signature:	/s/ Glenn Carlson
Name/Title:	Executive Director
Date:	02/09/2026